To better demonstrate TNBC-specific tumor heterogeneity, Lehmann et al. determined six TNBC subtypes with a distinct gene expression, including two basal-like subtypes (BL1 and BL2), an immunomodulatory subtype (IM), a mesenchymal subtype (M), a mesenchymal stem-like subtype (MSL), and an intraluminal androgen receptor (LAR) subtype (Lehmann et al., 2011). This evidence concerns the gene PTPRF and neoplasm.